Biolase (BIOL) Tops Q2 EPS by 109c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts BIOL Hot Sheet
Join SI Premium – FREE
Biolase (NASDAQ: BIOL) reported Q2 EPS of ($4.24), $1.09 better than the analyst estimate of ($5.33). Revenue for the quarter came in at $14.3 million versus the consensus estimate of $15.36 million.
For earnings history and earnings-related data on Biolase (BIOL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Robinhood (HOOD) Tops Q3 EPS by 5c, Misses on Revenue
- Nabors Industries (NBR) Misses Q3 EPS by 109c
- Artisan Partners Asset Management (APAM) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
